Literature DB >> 24588652

Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7.

Magnus Bäck1, William S Powell, Sven-Erik Dahlén, Jeffrey M Drazen, Jilly F Evans, Charles N Serhan, Takao Shimizu, Takehiko Yokomizo, G Enrico Rovati.   

Abstract

The endogenous ligands for the LT, lipoxin (LX) and oxoeicosanoid receptors are bioactive products produced by the action of the lipoxygenase family of enzymes. The LT receptors BLT1 and BLT2 , are activated by LTB4 and the CysLT1 and CysLT2 receptors are activated by the cysteinyl-LTs, whereas oxoeicosanoids exert their action through the OXE receptor. In contrast to these pro-inflammatory mediators, LXA4 transduces responses associated with the resolution of inflammation through the receptor FPR2/ALX (ALX/FPR2). The aim of the present review is to give a state of the field on these receptors, with focus on recent important findings. For example, BLT1 receptor signalling in cancer and the dual role of the BLT2 receptor in pro- and anti-inflammatory actions have added more complexity to lipid mediator signalling. Furthermore, a cross-talk between the CysLT and P2Y receptor systems has been described, and also the presence of novel receptors for cysteinyl-LTs, such as GPR17 and GPR99. Finally, lipoxygenase metabolites derived from ω-3 essential polyunsaturated acids, the resolvins, activate the receptors GPR32 and ChemR23. In conclusion, the receptors for the lipoxygenase products make up a sophisticated and tightly controlled system of endogenous pro- and anti-inflammatory signalling in physiology and pathology.
© 2014 The British Pharmacological Society.

Entities:  

Keywords:  LTs; cancer; cardiovascular; eicosanoids; inflammation; lipoxins; lipoxygenase; oxoeicosanoids; respiratory

Mesh:

Substances:

Year:  2014        PMID: 24588652      PMCID: PMC4128057          DOI: 10.1111/bph.12665

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  211 in total

1.  Pharmacological evidence for a novel cysteinyl-leukotriene receptor subtype in human pulmonary artery smooth muscle.

Authors:  Laurence Walch; Xavier Norel; Magnus Bäck; Jean-Pierre Gascard; Sven-Erik Dahlén; Charles Brink
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

2.  5-Oxo-ETE analogs and the proliferation of cancer cells.

Authors:  Joseph T O'Flaherty; LeAnn C Rogers; Christian M Paumi; Roy R Hantgan; Lance R Thomas; Carl E Clay; Kevin High; Yong Q Chen; Mark C Willingham; Pamela K Smitherman; Timothy E Kute; Anuradha Rao; Scott D Cramer; Charles S Morrow
Journal:  Biochim Biophys Acta       Date:  2005-08-30

3.  RanBPM protein acts as a negative regulator of BLT2 receptor to attenuate BLT2-mediated cell motility.

Authors:  Jun-Dong Wei; Joo-Young Kim; Ae-Kyoung Kim; Sung Key Jang; Jae-Hong Kim
Journal:  J Biol Chem       Date:  2013-08-08       Impact factor: 5.157

4.  A selective cysteinyl leukotriene receptor 2 antagonist blocks myocardial ischemia/reperfusion injury and vascular permeability in mice.

Authors:  Nathan C Ni; Dong Yan; Laurel L Ballantyne; Alma Barajas-Espinosa; Tim St Amand; Derek A Pratt; Colin D Funk
Journal:  J Pharmacol Exp Ther       Date:  2011-09-08       Impact factor: 4.030

5.  Formylpeptide receptor-2 contributes to colonic epithelial homeostasis, inflammation, and tumorigenesis.

Authors:  Keqiang Chen; Mingyong Liu; Ying Liu; Teizo Yoshimura; Wei Shen; Yingying Le; Scott Durum; Wanghua Gong; Chunyan Wang; Ji-Liang Gao; Philip M Murphy; Ji Ming Wang
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

6.  Identification of a novel human eicosanoid receptor coupled to G(i/o).

Authors:  Takeshi Hosoi; Yutaka Koguchi; Emiko Sugikawa; Aiko Chikada; Koji Ogawa; Naoki Tsuda; Naoki Suto; Shiho Tsunoda; Tomoyasu Taniguchi; Tetsuo Ohnuki
Journal:  J Biol Chem       Date:  2002-06-13       Impact factor: 5.157

7.  The Concise Guide to PHARMACOLOGY 2013/14: enzymes.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

8.  Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor.

Authors:  Fabricio A Pamplona; Juliano Ferreira; Octávio Menezes de Lima; Filipe Silveira Duarte; Allisson Freire Bento; Stefânia Forner; Jardel G Villarinho; Luigi Bellocchio; Luigi Bellochio; Carsten T Wotjak; Raissa Lerner; Krisztina Monory; Beat Lutz; Claudio Canetti; Isabelle Matias; João Batista Calixto; Giovanni Marsicano; Marilia Z P Guimarães; Reinaldo N Takahashi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-12       Impact factor: 11.205

9.  Pro-Resolving Lipid Mediators (SPMs) and Their Actions in Regulating miRNA in Novel Resolution Circuits in Inflammation.

Authors:  Antonio Recchiuti; Charles N Serhan
Journal:  Front Immunol       Date:  2012-10-22       Impact factor: 7.561

10.  Leukotriene D4 and interleukin-13 cooperate to increase the release of eotaxin-3 by airway epithelial cells.

Authors:  Véronique Provost; Anick Langlois; François Chouinard; Marek Rola-Pleszczynski; Jamila Chakir; Nicolas Flamand; Michel Laviolette
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

View more
  69 in total

Review 1.  Control of local immunity by airway epithelial cells.

Authors:  M Weitnauer; V Mijošek; A H Dalpke
Journal:  Mucosal Immunol       Date:  2015-12-02       Impact factor: 7.313

Review 2.  Activation and resolution of periodontal inflammation and its systemic impact.

Authors:  Hatice Hasturk; Alpdogan Kantarci
Journal:  Periodontol 2000       Date:  2015-10       Impact factor: 7.589

Review 3.  Anti-inflammatory therapies for atherosclerosis.

Authors:  Magnus Bäck; Göran K Hansson
Journal:  Nat Rev Cardiol       Date:  2015-02-10       Impact factor: 32.419

4.  5 S,15 S-Dihydroperoxyeicosatetraenoic Acid (5,15-diHpETE) as a Lipoxin Intermediate: Reactivity and Kinetics with Human Leukocyte 5-Lipoxygenase, Platelet 12-Lipoxygenase, and Reticulocyte 15-Lipoxygenase-1.

Authors:  Abigail R Green; Cody Freedman; Jennyfer Tena; Benjamin E Tourdot; Benjamin Liu; Michael Holinstat; Theodore R Holman
Journal:  Biochemistry       Date:  2018-11-15       Impact factor: 3.162

5.  15-Lipoxygenases regulate the production of chemokines in human lung macrophages.

Authors:  C Abrial; S Grassin-Delyle; H Salvator; M Brollo; E Naline; P Devillier
Journal:  Br J Pharmacol       Date:  2015-07-14       Impact factor: 8.739

6.  Biosynthesis and actions of 5-oxoeicosatetraenoic acid (5-oxo-ETE) on feline granulocytes.

Authors:  Chantal Cossette; Sylvie Gravel; Chintam Nagendra Reddy; Vivek Gore; Shishir Chourey; Qiuji Ye; Nathaniel W Snyder; Clementina A Mesaros; Ian A Blair; Jean-Pierre Lavoie; Carol R Reinero; Joshua Rokach; William S Powell
Journal:  Biochem Pharmacol       Date:  2015-05-29       Impact factor: 5.858

7.  Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949.

Authors:  Anna K Stalder; Dominik Lott; Daniel S Strasser; Hans G Cruz; Andreas Krause; Peter M A Groenen; Jasper Dingemanse
Journal:  Br J Clin Pharmacol       Date:  2016-11-15       Impact factor: 4.335

Review 8.  Resolution of inflammation: a new therapeutic frontier.

Authors:  James N Fullerton; Derek W Gilroy
Journal:  Nat Rev Drug Discov       Date:  2016-03-29       Impact factor: 84.694

Review 9.  Leukotriene receptors as potential therapeutic targets.

Authors:  Takehiko Yokomizo; Motonao Nakamura; Takao Shimizu
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

10.  Intrathecal administration of Resolvin D1 and E1 decreases hyperalgesia in mice with bone cancer pain: Involvement of endocannabinoid signaling.

Authors:  Iryna A Khasabova; Mikhail Y Golovko; Svetlana A Golovko; Donald A Simone; Sergey G Khasabov
Journal:  Prostaglandins Other Lipid Mediat       Date:  2020-07-31       Impact factor: 3.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.